← Leaderboards
Roberto Irenardo Vazquez Padron
University Of Miami School Of Medicine
$5,595,653
Attributed
$10,395,746
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $965.9K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,395,746 · 8
VA$0 · 3
By mechanism
R01$9,774,194 · 6
K01$429,677 · 1
R21$191,875 · 1
I01$0 · 2
IK6$0 · 1
Top collaborators
- Yan-Ting E. Shiu10 shared
- Vineet Gupta7 shared
- Fotios Matthaios Andreopoulos5 shared
- Loay Hatem Salman5 shared
- Omaida C Velazquez5 shared
- Keith A Webster4 shared
- Sharon J Elliot1 shared
- Marilyn K Glassberg1 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Jose Szapocznik$79,209,602
- Mustafa Tekin$15,488,636
- Glen N. Barber$22,145,694
- Savita Pahwa$35,297,534
- Jacob L McCauley$18,731,270
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsPreventNovel TherapeuticsPublishingComplicationNew Therapeutic TargetFunctional DisorderMediatingOutcome StudyHyperplasiaDesignGenesCellsMorbidity - Disease RateSmooth Muscle MyocytesMedical ComplicationArteriovenous FistulaHemodialysisPhenotypeFistulaVenousBlood FlowStenosisSecure
Grant awards (40)
Integrin Activation to Prevent Early Arteriovenous Fistula Failure in End-stage Renal Disease Patients$469,978
R01 · FY2025 · DK · contact PI
The Role of Vascular Calprotectin in Arteriovenous Fistula Maturation$423,830
R01 · FY2025 · DK · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Integrin Activation to Prevent Early Arteriovenous Fistula Failure in End-stage Renal Disease Patients$557,622
R01 · FY2024 · DK · contact PI
The Role of Vascular Calprotectin in Arteriovenous Fistula Maturation$408,242
R01 · FY2024 · DK · contact PI
BCCMA: Cardiovascular Remodeling following Arteriovenous Fistula Creation: Type VIII Collagen Contributes to Adverse Arteriovenous Fistula Remodeling$0
I01 · FY2024 · VA · contact PI
The Role of Vascular Calprotectin in Arteriovenous Fistula Maturation$433,140
R01 · FY2023 · DK · contact PI
Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure$362,106
R01 · FY2023 · DK · contact PI
The Multiple Roles of Lysyl Oxidase in Arteriovenous Fistula Failure$0
I01 · FY2023 · VA · contact PI
The Role of Vascular Calprotectin in Arteriovenous Fistula Maturation$448,286
R01 · FY2022 · DK · contact PI
Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure$375,714
R01 · FY2022 · DK · contact PI
Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure$7,253
R01 · FY2022 · DK · contact PI
The Multiple Roles of Lysyl Oxidase in Arteriovenous Fistula Failure$0
I01 · FY2022 · VA · contact PI
Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure$379,335
R01 · FY2021 · DK · contact PI
Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure$87,041
R01 · FY2021 · DK · contact PI
The Multiple Roles of Lysyl Oxidase in Arteriovenous Fistula Failure$0
I01 · FY2021 · VA · contact PI
Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure$382,889
R01 · FY2020 · DK · contact PI
Does sex matter? Targeting sex differences in age-related lung disease$191,875
R21 · FY2020 · AG · contact PI
Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure$79,788
R01 · FY2020 · DK · contact PI
The Multiple Roles of Lysyl Oxidase in Arteriovenous Fistula Failure$0
I01 · FY2020 · VA · contact PI
C-Kit in atherosclerosis$466,972
R01 · FY2019 · HL · contact PI
Dual Role of Lysyl Oxidase in Arteriovenous Fistula Failure$399,745
R01 · FY2019 · DK · contact PI
C-Kit in atherosclerosis$466,401
R01 · FY2018 · HL · contact PI
C-Kit in atherosclerosis$383,750
R01 · FY2017 · HL · contact PI
C-Kit in Atherosclerosis$82,098
R01 · FY2017 · HL · contact PI
Vascular Progenitor Cells in Arteriovenous Fistula Stenosis$419,823
R01 · FY2016 · DK · contact PI
C-Kit in atherosclerosis$383,750
R01 · FY2016 · HL · contact PI
Leukadherins as novel compounds for treating restenosis$461,432
R01 · FY2015 · HL · contact PI
Vascular Progenitor Cells in Arteriovenous Fistula Stenosis$333,863
R01 · FY2015 · DK · contact PI
Vascular Progenitor Cells in Arteriovenous Fistula Stenosis$85,960
R01 · FY2015 · DK · contact PI
Leukadherins as novel compounds for treating restenosis$374,850
R01 · FY2014 · HL · contact PI
Vascular Progenitor Cells in Arteriovenous Fistula Stenosis$333,863
R01 · FY2014 · DK · contact PI
Leukadherins as novel compounds for treating restenosis$85,960
R01 · FY2014 · HL · contact PI
Leukadherins as novel compounds for treating restenosis$364,140
R01 · FY2013 · HL · contact PI
Vascular Progenitor Cells in Arteriovenous Fistula Stenosis$333,863
R01 · FY2013 · DK · contact PI
Leukadherins as novel compounds for treating restenosis$382,500
R01 · FY2012 · HL · contact PI
Genetics of In-Stent Restenosis: The Human Strategy$109,078
K01 · FY2012 · HL · contact PI
Genetics of In-Stent Restenosis: The Mouse to Human Strategy$109,078
K01 · FY2011 · HL · contact PI
Genetics of In-Stent Restenosis: The Mouse to Human Strategy$106,844
K01 · FY2010 · HL · contact PI
Genetics of In-Stent Restenosis: The Mouse to Human Strategy$104,677
K01 · FY2009 · HL · contact PI